Dashboard
Manage Tickers

VNDA Vanda Pharmaceuticals Inc.

Nasdaq vandapharma.com


$ 4.50 $ 0.00 (0 %)    

Thursday, 06-Nov-2025 04:00:00 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 624.93 $ 0.00 (0 %)
DIA $ 473.48 $ 0.00 (0 %)
SPY $ 679.10 $ 0.00 (0 %)
TLT $ 89.35 $ 0.00 (0 %)
GLD $ 369.14 $ 0.00 (0 %)
$ 4.44
$ 4.45
$ 4.46 x 5,000
$ 4.50 x 8,800
-- - --
$ 3.81 - $ 5.70
627,488
na
262.39M
$ 0.62
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-30-2025 09-30-2025 10-Q
2 07-31-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 02-14-2025 12-31-2024 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-01-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 02-08-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 07-28-2023 06-30-2023 10-Q
11 05-03-2023 03-31-2023 10-Q
12 02-09-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-06-2022 03-31-2022 10-Q
16 02-24-2022 12-31-2021 10-K
17 11-04-2021 09-30-2021 10-Q
18 07-29-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 02-11-2021 12-31-2020 10-K
21 10-29-2020 09-30-2020 10-Q
22 08-06-2020 06-30-2020 10-Q
23 05-07-2020 03-31-2020 10-Q
24 02-26-2020 12-31-2019 10-K
25 11-07-2019 09-30-2019 10-Q
26 08-01-2019 06-30-2019 10-Q
27 05-03-2019 03-31-2019 10-Q
28 02-19-2019 12-31-2018 10-K
29 11-07-2018 09-30-2018 10-Q
30 08-02-2018 06-30-2018 10-Q
31 05-02-2018 03-31-2018 10-Q
32 02-15-2018 12-31-2017 10-K
33 11-08-2017 09-30-2017 10-Q
34 08-03-2017 06-30-2017 10-Q
35 05-03-2017 03-31-2017 10-Q
36 02-17-2017 12-31-2016 10-K
37 11-03-2016 09-30-2016 10-Q
38 07-28-2016 06-30-2016 10-Q
39 05-05-2016 03-31-2016 10-Q
40 02-12-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

this-docebo-analyst-begins-coverage-on-a-bullish-note-here-are-top-3-initiations-for-wednesday
This Docebo Analyst Begins Coverage On A B...
11/05/2025 13:48:58

this-trex-company-analyst-turns-bearish-here-are-top-5-downgrades-for-wednesday
This Trex Company Analyst Turns Bearish; H...
11/05/2025 12:22:37

b-riley-securities-initiates-coverage-on-vanda-pharmaceuticals-with-buy-rating-announces-price-target-of-11
B. Riley Securities Initiates Coverage On ...
11/05/2025 11:22:03

B. Riley Securities analyst Madison El-Saadi initiates coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy rating and...

cantor-fitzgerald-maintains-overweight-on-vanda-pharmaceuticals-lowers-price-target-to-11
Cantor Fitzgerald Maintains Overweight on ...
10/30/2025 13:48:50

Cantor Fitzgerald analyst Olivia Brayer maintains Vanda Pharmaceuticals (NASDAQ:VNDA) with a Overweight and lowers the price...

vanda-pharmaceuticals-narrows-fy2025-sales-guidance-from-210000m-250000m-to-210000m-230000m-vs-224977m-est
Vanda Pharmaceuticals Narrows FY2025 Sales...
10/29/2025 20:02:53

Vanda Pharmaceuticals (NASDAQ:VNDA) narrows FY2025 sales outlook from $210.000 million-$250.000 million to $210.000 million-$23...

vanda-pharma-q3-eps-038-beats-045-estimate-sales-56258m-miss-58733m-estimate
Vanda Pharma Q3 EPS $(0.38) Beats $(0.45) ...
10/29/2025 20:02:22

Vanda Pharma (NASDAQ:VNDA) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.45) ...

earnings-scheduled-for-october-29-2025
Earnings Scheduled For October 29, 2025
10/29/2025 11:11:56

jim-cramer-calls-cameco-a-good-company-recommends-buying-this-financial-stock
Jim Cramer Calls Cameco A Good Company, Re...
10/27/2025 12:05:50

On CNBC's "Mad Money Lightning Round," Jim Cramer discussed Apollo Global, National Fuel Gas, Main Street Capital a...

vanda-pharmaceuticals-agrees-on-a-collaborative-framework-with-the-fda-for-the-resolution-of-certain-disputes-regarding-hetlioz-and-tradipitant
Vanda Pharmaceuticals Agrees On A Collabor...
10/01/2025 21:08:10

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that it has agreed on a collaborative framework with the U.S. ...

anaptysbio-charts-path-to-split-into-two-public-companies-by-2026
AnaptysBio Charts Path To Split Into Two P...
09/30/2025 17:59:14

AnaptysBio plans to separate into Royalty Management Co. and Biopharma Co. by 2026, with each positioned for growth in distinct...

vanda-pharmaceuticals-announced-the-publication-of-an-article-titled-melatonin-agonist-tasimelteon-improves-sleep-in-patients-with-primary-insomnia-a-multicenter-randomized-double-blind-placebo-controlled-trial-in-plos-one-a-leading-open-access-journal
Vanda Pharmaceuticals Announced The Public...
09/25/2025 12:08:08

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced the publication of an article titled "Melatonin agonist t...

vanda-pharmaceuticals-receives-fda-orphan-drug-designation-for-vgt-1849b-a-peptide-nucleic-acid-based-candidate-in-polycythemia-vera
Vanda Pharmaceuticals Receives FDA Orphan ...
08/28/2025 11:04:43

vanda-pharmaceuticals-asked-martin-makary-to-review-the-decision-made-by-jacqueline-corrigan-curay-the-departing-director-of-the-fdas-center-for-drug-evaluation-and-research-days-before-her-retirement-that-upholds-an-office-of-generic-drugs-decision-to-approve-two-generic-versions-of-hetlioz
Vanda Pharmaceuticals Asked Martin Makary ...
08/21/2025 20:46:16

WASHINGTON, Aug. 21, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that it has asked Ma...

hc-wainwright--co-reiterates-buy-on-vanda-pharmaceuticals-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Vand...
08/21/2025 11:20:35

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and maintains $...

vanda-wins-major-court-battle-for-jet-lag-drug-forcing-fda-to-revisit-rejection
Vanda Wins Major Court Battle For Jet Lag ...
08/18/2025 11:08:23

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that it secured a landmark victory over the U.S. Food and Drug...

vanda-pharmaceuticals-affirms-fy2025-sales-guidance-of-21000m-25000m-vs-22772m-est
Vanda Pharmaceuticals Affirms FY2025 Sales...
07/31/2025 11:37:36

Vanda Pharmaceuticals (NASDAQ:VNDA) affirms FY2025 sales outlook from $210.00 million-$250.00 million to $210.00 million-$250.0...

vanda-pharma-q2-eps-046-misses-036-estimate-sales-5259m-miss-5460m-estimate
Vanda Pharma Q2 EPS $(0.46) Misses $(0.36)...
07/31/2025 11:36:39

Vanda Pharma (NASDAQ:VNDA) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.36...

Core News & Articles
Earnings Scheduled For July 31, 2025
07/31/2025 08:32:50

vanda-pharma-announces-first-dose-in-first-in-human-clinical-trial-to-evaluate-safety-and-tolerability-of-vca-894a-aso-therapeutic-for-patient-with-rare-variant-in-ighmbp2-gene-causing-charcot-marie-tooth-disease-type-2s
Vanda Pharma Announces First Dose In First...
06/10/2025 12:12:10

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the first dose in the first-in-human clinical trial to evalua...

cantor-fitzgerald-assumes-vanda-pharmaceuticals-at-overweight-announces-price-target-of-13
Cantor Fitzgerald Assumes Vanda Pharmaceut...
05/14/2025 14:04:26

Cantor Fitzgerald analyst Olivia Brayer assumes Vanda Pharmaceuticals (NASDAQ:VNDA) with a Overweight rating and announces P...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION